AR132824A1 - USO TERAPÉUTICO DE ANTICUERPOS ANTI-Ab / TfR BIESPECÍFICOS - Google Patents
USO TERAPÉUTICO DE ANTICUERPOS ANTI-Ab / TfR BIESPECÍFICOSInfo
- Publication number
- AR132824A1 AR132824A1 ARP240101383A ARP240101383A AR132824A1 AR 132824 A1 AR132824 A1 AR 132824A1 AR P240101383 A ARP240101383 A AR P240101383A AR P240101383 A ARP240101383 A AR P240101383A AR 132824 A1 AR132824 A1 AR 132824A1
- Authority
- AR
- Argentina
- Prior art keywords
- bispecific anti
- therapeutic use
- bispecific
- tfr antibodies
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
En la presente se informa un anticuerpo biespecífico que se une específicamente a la proteína Ab humana y al receptor de transferrina humano (anticuerpo anti-Ab / TfR biespecífico) así como el uso de tales anticuerpos biespecíficos como un medicamento en el tratamiento de la enfermedad de Alzheimer, que incluye donde el anticuerpo biespecífico se administra por vía intravenosa a una dosis de 0,2 mg/kg a 7,2 mg/kg una vez cada cuatro semanas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP23/64623 | 2023-05-31 | ||
| EPPCT/EP23/79276 | 2023-10-20 | ||
| EPPCT/EP24/55668 | 2024-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132824A1 true AR132824A1 (es) | 2025-07-30 |
Family
ID=91375896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101383A AR132824A1 (es) | 2023-05-31 | 2024-05-31 | USO TERAPÉUTICO DE ANTICUERPOS ANTI-Ab / TfR BIESPECÍFICOS |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240417451A1 (es) |
| EP (1) | EP4719471A1 (es) |
| JP (2) | JP7802859B2 (es) |
| KR (1) | KR20260020387A (es) |
| CN (1) | CN121263206A (es) |
| AR (1) | AR132824A1 (es) |
| AU (1) | AU2024283314A1 (es) |
| IL (1) | IL324430A (es) |
| MX (1) | MX2025014083A (es) |
| TW (1) | TW202515904A (es) |
| WO (1) | WO2024246085A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR106189A1 (es) * | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| WO2026119384A1 (en) * | 2024-12-04 | 2026-06-11 | F. Hoffmann-La Roche Ag | Therapeutic use of bispecific anti-abeta/tfr antibodies |
| JP2026096188A (ja) * | 2024-12-02 | 2026-06-12 | エフ. ホフマン-ラ ロシュ アーゲー | 二重特異性抗Aベータ/TfR抗体の治療的使用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| CN101553504A (zh) | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
| ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
| JP5859148B2 (ja) | 2012-03-08 | 2016-02-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Aβ抗体製剤 |
| JP2014001232A (ja) | 2013-09-02 | 2014-01-09 | Janssen Alzheimer Immunotherapy | アミロイド原性疾患の処置 |
| AU2016282334B2 (en) * | 2015-06-24 | 2022-07-21 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| CR20230253A (es) * | 2020-11-16 | 2023-07-26 | Hoffmann La Roche | Glucoformas de fab ricas en manosa |
| CN115227813A (zh) | 2021-04-23 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | 一种含抗Abeta抗体的药物组合物 |
-
2024
- 2024-05-29 WO PCT/EP2024/064691 patent/WO2024246085A1/en not_active Ceased
- 2024-05-29 IL IL324430A patent/IL324430A/en unknown
- 2024-05-29 KR KR1020257039974A patent/KR20260020387A/ko active Pending
- 2024-05-29 CN CN202480035876.1A patent/CN121263206A/zh active Pending
- 2024-05-29 US US18/677,151 patent/US20240417451A1/en active Pending
- 2024-05-29 AU AU2024283314A patent/AU2024283314A1/en active Pending
- 2024-05-29 EP EP24730638.4A patent/EP4719471A1/en active Pending
- 2024-05-30 JP JP2024088202A patent/JP7802859B2/ja active Active
- 2024-05-30 TW TW113120107A patent/TW202515904A/zh unknown
- 2024-05-31 AR ARP240101383A patent/AR132824A1/es unknown
-
2025
- 2025-11-25 MX MX2025014083A patent/MX2025014083A/es unknown
-
2026
- 2026-01-07 JP JP2026001236A patent/JP2026065045A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN121263206A (zh) | 2026-01-02 |
| EP4719471A1 (en) | 2026-04-08 |
| MX2025014083A (es) | 2026-01-07 |
| WO2024246085A1 (en) | 2024-12-05 |
| TW202515904A (zh) | 2025-04-16 |
| AU2024283314A1 (en) | 2025-11-13 |
| IL324430A (en) | 2026-01-01 |
| JP7802859B2 (ja) | 2026-01-20 |
| JP2024178124A (ja) | 2024-12-24 |
| KR20260020387A (ko) | 2026-02-11 |
| JP2026065045A (ja) | 2026-04-14 |
| US20240417451A1 (en) | 2024-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003888A (es) | Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos. | |
| MX2025014083A (es) | Uso terapeutico de anticuerpos biespecificos anti proteina beta-amiloide (abeta)/receptor de transferrina (tfr) | |
| US20100209430A1 (en) | Method for treating erectile dysfunction | |
| CL2020002075A1 (es) | Métodos para tratar el cáncer con anticuerpos anti-pd1. | |
| US20150023972A1 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| CR10244A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| CL2022002093A1 (es) | Anticuerpos para usar en terapia. | |
| Harris | US maternal mortality continues to worsen | |
| ECSP23076276A (es) | Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 | |
| CN102343089A (zh) | 一种治疗乳癌的医药组成物 | |
| Harris | CDC: Candida auris fungal infections and drug resistance on the rise | |
| BR112020014849A2 (pt) | Anticorpo recombinante isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma de infecção por influenza | |
| Mahboob et al. | Large vessel stroke and COVID-19: case report and literature review | |
| Zydb et al. | Efficacy of oral ketamine combined with psychotherapy for treatment resistant depression | |
| Harris | Drought caused 43 000 deaths in Somalia in 2022, half among children | |
| Hungria et al. | Impact of long-term treatment with belantamab mafodotin on safety and efficacy outcomes in patients with relapsed/refractory multiple myeloma in DREAMM-3 | |
| Kuter et al. | A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3 | |
| PE20250161A1 (es) | Dosis para tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3 en pacientes mayores | |
| Marini et al. | Rozanolixizumab treatment patterns in patients with generalised myasthenia gravis: Post hoc analysis | |
| CR20220041A (es) | Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab | |
| Harris | World on Path to Eliminate AIDS as a Global Threat by 2030 | |
| CR20250089A (es) | Composiciones para el tratamiento de una enfermedad o trastorno mediado por linfocitos t portadoras del segmento trbv9 dentro del receptor de células t | |
| RU2013124994A (ru) | КОМБИНАЦИЯ БЕВАЦИЗУМАБА И 2,2-ДИМЕТИЛ-N-((S)-6-ОКСО-6,7-ДИГИДРО-5Н-ДИБЕНЗО[b,d]АЗЕПИН-7-ИЛ)-N'-(2,2,3,3,3-ПЕНТАФТОР-ПРОПИЛ)-МАЛОНАМИДА ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| Harris | Cold Virus Provided Cross-reactivity Against SARS-CoV-2 in Children | |
| AR131609A1 (es) | Método de tratamiento de una enfermedad o trastorno mediado por linfocitos t portadoras del segmento trbv9 dentro del receptor de células t |